Cetuximab & Nivolumab in Patients With Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma

Conditions:   Squamous Cell Carcinoma of the Oropharynx;   Squamous Cell Carcinoma of the Larynx;   Squamous Cell Carcinoma of the Oral Cavity;   Squamous Cell Carcinoma of the Hypopharynx;   Squamous Cell Carcinoma of the Paranasal Sinus;   Head and Neck Squamous Cell Carcinoma;   Squamous Cell Cancer;   Head and Neck Carcinoma
Interventions:   Drug: Nivolumab;   Drug: Cetuximab
Sponsors:   H. Lee Moffitt Cancer Center and Research Institute;   James and Esther King Biomedical Research Program;   Eli Lilly and Company
Recruiting

http://ift.tt/2ANwsxL